Gene Logic - eine Biotech-Software-Perle aus USA... - 500 Beiträge pro Seite

[Börsenspezi]

...910845
z.Zt. meilenweit von alten Höchstkursen (109 Euro) entfernt;
Boden gebildet bei 23 Euro; spekulativer Kauf, KZ kurzfristig 38 Euro; 9-Monatszahlen Anfang November.

[Meier M]

Servus Börsenspezi,

alte höchstkurse waren zw. 150 u. 156€<! bin aber froh das schön langsam eine breite front
an GLGC interesse zeigt, super! sollten die zahlen wie erwartet sein und nächsten samstag
das meeting einige großinvestoren anlocken, so sehe ich die 38€ als taschengeld!

schönes wochende noch


mfg

[tjatja]

Hi meier m

dein Wort in Gottes Ohr. Glaubes aber auch den die Rakete ist gerade vorm starten!


Gruß





CAMILO MARTINEZ remembers the joke circulating around Wall Street not
that long ago: If you want to cause a buying stampede among
investors, just insert the prefix "gen" into a company`s name.

Dr. Martinez, an internist who is a co- manager of the Dresdner
RCM Biotechnology fund, witnessed the market frenzy that began in
the fall of 1999, as some genomics stocks started to more than
quadruple in value. Investors saw a bright future in genomics,
believing that the science, which identifies the genetic roots of
illnesses, would lead to the development of lucrative
life-prolonging drugs.

Analysts, though, had warned that the industry was still in its
infancy and that most genomics companies could expect to see losses
for the next three to five years. By last spring, as the overall
market began to tumble, investors began pulling out of many
genomics stocks almost as quickly as they had plunged in.

The sector generally remains depressed these days, even though
researchers announced in June that they had decoded the human
genome a landmark scientific discovery. (Celera Genomics, a unit
of the PE Corporation, and the publicly financed Human Genome
Project said they had produced a rough draft of the body`s
estimated 100,000 genes.)

Many genomics stocks are still off considerably from their 52-week
highs. Celera, for example, hit $276 a share last March, but now
trades at $67.25.

Still, several genomics companies are busy going public, with
roughly a half-dozen more initial public offerings expected through
this fall. Charles C. Duncan, a biotechnology analyst at Prudential
Securities, said that about three dozen genomics companies had
already gone public this year, a rate he called "amazing."

But for investors, picking apart the genomics industry can seem as
complicated as picking apart the genes themselves.

"A fundamental problem is that people do not understand exactly
what these companies do, or what their business models are for the
long term," Dr. Martinez said.

Meirav Chovav, an analyst at Salomon Smith Barney, agreed: "What
we`re hearing from both institutional and individual investors is
that everything is confusing in terms of what fits in where."

Mr. Duncan said the genomics industry was starting to sort itself
into four broad camps.

The first group is the technology providers that supply tools like
the so-called gene chips used in analyzing genomics data, along
with DNA sequencers and bioinformatics software. It includes
companies like Affymetrix, LION Bioscience, Gene Logic and Applied
Biosystems, Celera`s sister company, which was formerly known as PE
Biosystems.

The second is information providers, like Celera and Incyte
Genomics, that compile genetic information into databases and then
sell subscription rights to drug companies.

In the third group are the research companies like Sangamo
Biosciences, Lexicon and Genome Therapeutics; they generally
operate under research agreements to provide some sort of valuable
technology to biotechnology or pharmaceutical companies. The fourth
set uses genomics to develop better diagnostics and pharmaceutical
products. It includes companies like Myriad Genetics, Human Genome
Sciences and Millennium Pharmaceuticals.


SOME money managers say genomics investors have been
cherry-picking throughout the sector lately.

Steven Newby, portfolio manager for GenomicsFund.com, a mutual
fund that started in March, said he thought that investors had lost
their earlier zeal for companies that sell products like gene
chips, bioinformatics software and genomic databases and are moving
instead to those that are actually developing drugs. He pointed out
that Affymetrix, Celera and Gene Logic were off between 65 and 70
percent from their 52-week highs, while the stock of Millennium
recently reached a new high, and Human Genome Sciences was not too
far from the high it set last spring.

"There`s been quite a restructuring of investor interest from the
spring, when investors simply bought genomics stocks lock, stock
and barrel," Mr. Newby said.

Because genomics stocks have proved so volatile, he recommended
that investors invest in a variety of companies across the entire
sector. The largest genomics holdings in his fund are Millennium
Pharmaceuticals, Human Genome Sciences and Medarex, a drug
developer.

Dr. Martinez`s fund also invests in Millennium Pharmaceuticals and
Human Genome Sciences, though he also has positions in eight
companies that are mostly suppliers to the genomics industry, like
Charles River Laboratories, a large provider of laboratory animals
used in research.

"Not only do we think that big suppliers are a relatively low risk
to play the genomics industry, but many of these companies have
been profitable for many years and have lots of cash on hand," Dr.
Martinez said.

Mr. Duncan said he liked a diverse group of genomics companies,
although he is more focused on those that are aimed at drug
development. Among his favorites are Celera, Genome Therapeutics,
Sangamo Biosciences and Human Genome Sciences. He also likes
Curagen and Tularik, which are involved mainly in drug discovery
and development, and Genomica, which provides bioinformatics
software.


WHILE some analysts say the stock of Human Genome Sciences is
overvalued they are generally cautious about the clinical
benefits of the drugs that the company currently has in testing
Mr. Duncan has a 12-month target of $125 on the stock, which closed
on Friday at $88.13. The company had a two-for-one stock split on
Oct. 5.

Mr. Duncan`s top pick is Myriad Genetics. He sees it as unusually
prolific in discovering disease-related genes but also as an early
leader in the field of proteomics, which many scientists generally
regard as the next step after genomics research. Proteomics
involves the large-scale study of the proteins that are made by
genes.

Proteomics companies have not eluded the radar screens of
investors lately. When Ciphergen Biosystems and Genomica each went
public on Sept. 29, the stock of Ciphergen, a proteomics company
that had just $5 million in revenue in 1999, doubled from $16 to
$32, while Genomica, the bioinformatics company, rose just 44
cents. Ciphergen Biosystems now trades at $29.75, while Genomica is
at $13.

Mr. Newby said he thought that investors were latching onto
proteomics as the latest buzzword in the genomics industry.

"I first noticed the interest in the spring, when genomics stocks
were down, and investors were looking for something new," he said.

Buzzwords worry Dr. Martinez, who said genomics investors have
already spent the last year jumping from one trend to another.
Rather than focusing on trends, he said, investors should remember
that the relationship between genes and diseases is so complex that
the efforts to date have simply been "a race to the starting line."

Mr. Newby agreed and recommended some caution.

"This is an
industry with open-ended potential over the next 20 to 50 years,"
he said. "There`s no reason why you have to be right there right
now with all your money."
-NOTE
Livetraders.net strongly recommends you research and discuss any
investment decisions with a licensed professional. The information
and data prepared in this report were deemed from sources to be
reliable. This memorandum is based on information available to the
public. No representation is made that is it is accurate and
complete. This memorandum is not an offer to buy or sell or a
solicitation of an offer to buy or sell the securities mentioned.

[tjatja]

könnten diese Woche schnell auf 30€ steigen!


ene Logic Reports Third Quarter 2000 Results -- Revenues
Increased 25% over Prior Year`s Third Quarter --

GAITHERSBURG, Md.--(BW HealthWire)--Oct. 30, 2000--Gene Logic Inc. (Nasdaq: GLGC),
a leading provider of genomic information products, today announced its results for the third
quarter of 2000.

Revenues for the three months ended September 30, 2000 were $5.3 million, a 25% increase
over the $4.2 million reported for the comparable period of 1999. Revenues for the nine months
ended September 30, 2000 were $16.8 million, a 25% increase over the $13.5 million reported for
the comparable period of 1999. This increase resulted from increased revenues for subscriptions
to the Company`s GeneExpressTM Suite of databases.

For the three months ended September 30, 2000, the Company reported a net loss of $8.0 million,
or $0.31 per share, compared to a net loss of $5.4 million, or $0.27 per share, for the same period
in 1999. The net loss for the first nine months of 2000 was $18.0 million, or $0.72 per share,
compared to $14.7 million, or $0.74 per share, for the same period in 1999.

Operating expenses for the three months ended September 30, 2000 were $17.1 million,
compared to $9.7 million for the comparable period of 1999. Operating expenses for the nine
months ended September 30, 2000 were $44.9 million, compared to $28.7 million for the
comparable period of 1999. The increase in operating expenses was attributable to the continuing
expansion of database content and infrastructure, including increased sales and marketing
efforts, necessary to support existing and planned growth of the GeneExpressTM Suite of
products.

As of September 30, 2000, Gene Logic had approximately $231.4 million in cash and cash
equivalents.

"Through the first ten months of 2000, our closure rate of seven pharmaceutical and
biotechnology company subscriptions to the GeneExpressTM Suite continues to keep pace with
our goal of ten customers by the end of the year," commented Philip L. Rohrer, Jr., Chief
Financial Officer of Gene Logic. "During the third quarter, the continued investments in our sales
and marketing efforts began to pay off. For the remainder of 2000 and into 2001 we look to
continue to aggressively sign new users to the GeneExpressTM Suite as its extraordinary value
and utility as a genomics information tool becomes more widely known, expand the breadth and
depth of the content and functionality of the GeneExpressTM Suite, and sign additional strategic
partnership opportunities where prudent." Third Quarter / Early Fourth Quarter 2000 Highlights

Product Development Gene Logic completed the update of the content of the
GeneExpressTM Suite using the new Affymetrix, Inc. HU-95 Human Genome
GeneChip(R) set which includes 60,000 human genes and ESTs, replacing the HU-35
Human Genome GeneChip(R) set which included 42,000 human genes and ESTs.

Gene Logic completed the latest upgrade to the GeneExpressTM 2000

software interface, expanding from version 1.1 to version 1.2, and

began introducing the new interface to all current GeneExpressTM

Suite subscribers.

Business Partnerships Gene Logic announced a business development collaboration with
Amersham Pharmacia Biotech K.K. to market and sell Gene Logic`s entire line of
genomic information products to the Japanese pharmaceutical and biotechnology market.

Business Development Gene Logic signed a two-tiered agreement with UCB Pharma
encompassing the expansion of an existing custom discovery partnership for a custom
gene expression database in the area of allergy and asthma and a subscription to a
CustomSuite of the GeneExpressTM Suite including access to the Atlas DataSuite, a
subset focused on normal gene expression, and a separate yet integrated custom database
incorporating their proprietary data.

Investors may listen to Gene Logic`s senior management discuss the details of this
announcement during a conference call scheduled for Monday, October 30, 2000 from 9:00 to
10:30 a.m. EST by dialing: domestic - 800/283-1693; or international - 703/736-7227 (NO
PASSCODE). A replay of this call will be available through Monday, November 13, 2000 by
dialing either of the previously mentioned numbers. A webcast of the call will also be available
for live participation accessed from the Company`s Web site - www.genelogic.com. The
webcast will be archived following the call for the next 90 days and is located at the Company
Web site - www.genelogic.com. Gene Logic Inc. Overview

Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and
development of pharmaceutical, biotechnology, health care, and life science products through the
systematic and industrialized application of genomics and bioinformatics. Gene Logic has built
and is commercializing the world`s most comprehensive survey of gene expression in human and
animal tissues. Gene expression, which is the degree to which genes in a cell are switched on or
off, or regulated, is information critical to understanding the functions of genes. Gene Logic
markets two types of gene expression database products to the global pharmaceutical,
biotechnology, health care and life science industries: its custom databases and related software
products and the GeneExpressTM Suite of databases. The GeneExpressTM Suite can be used
to discover and validate novel drug targets, develop and prioritize therapeutic compounds and
facilitate clinical trials and patient management. Today, a number of pharmaceutical and
biotechnology companies use Gene Logic`s various gene expression products for drug discovery,
predictive toxicology and diagnostic applications. For more information about Gene Logic, visit
the company`s Web site at www.genelogic.com or telephone toll-free on 1-800-GENELOGIC. -
more - All statements in this press release that are not historical are considered forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding Gene Logic`s "expectations," "beliefs," "goals," "hopes,"
"strategies," or the like. Such statements are subject to risks and uncertainties that could cause
actual results to differ materially for Gene Logic from those projected, including, but not limited
to, risks and uncertainties relating to technological approaches, product development, production,
market acceptance, cost and pricing of Gene Logic products, utility of genomic information in
drug discovery and development, dependence on collaborative partners, sole source suppliers,
competition, ability to sign new subscribers, customer renewals and terminations, intellectual
property of Gene Logic and others, and patent protection and litigation. These and other risk
factors are discussed in Gene Logic`s Annual Report on Form 10-K for the year ended
December 31, 1999 and Gene Logic`s other SEC reports, including its Quarterly Reports on
Form 10-Q. Gene Logic expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in
Gene Logic`s expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based. Financial tables follow.

GENE LOGIC INC.
Consolidated Condensed Statements of Operations
(In thousands, except per share amounts)
(unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
------------------------ ---------------------
2000 1999 2000 1999
------------ ----------- ----------- ---------

Revenues $ 5,269 $ 4,223 $ 16,811 $ 13,502

Expenses:
Research and
development 11,955 7,020 31,049 21,506
Selling, general
and
administrative 4,731 2,335 12,662 6,094
Amortization
of goodwill 381 381 1,143 1,143
------------ ----------- ----------- ---------

Total expenses 17,067 9,736 44,854 28,743
------------ ----------- ----------- ---------

Loss from operations (11,798) (5,513) (28,043) (15,241)

Interest (income),
net (3,828) (126) (9,957) (589)
Other (income) -- -- (234) (30)
Income tax expense -- -- 160 100
------------ ----------- ----------- ---------

Net loss $ (7,970) $ (5,387) $ (18,012) $ (14,722)
------------ ----------- ----------- ---------
------------ ----------- ----------- ---------

Basic and Diluted
Net Loss Per Common
Share $ (0.31) $ (0.27) $ (0.72) $ (0.74)
------------ ----------- ----------- ---------
------------ ----------- ----------- ---------

Shares Used in
Computing Basic
and Diluted Net 25,798 19,887 24,939 19,799
Loss Per Common
Share
------------ ----------- ----------- ---------
------------ ----------- ----------- ---------


GENE LOGIC INC.
Consolidated Condensed Balance Sheets
(In thousands)

September 30, December 31,
2000 1999
-------------------- ---------------
(unaudited)
ASSETS
Current assets:
Cash, cash equivalents
and marketable
securities
available-for-sale $ 231,419 $ 12,446
Due from collaborators 3,008 3,549
Inventory 1,530 1,735
Prepaid expenses 1,891 822
Other current assets 2,675 1,335
-------------------- --------------
Total current assets 240,523 19,887
Property and equipment, net 13,508 10,527
Long-term investments 9,081 1,000
Note receivable from employee 75 735
Goodwill, net 4,582 5,725
Intangibles and other assets,
net 8,197 3,292
-------------------- --------------
Total assets $ 275,966 $ 41,166
-------------------- --------------

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $ 4,378 $ 4,506
Accrued expenses 5,121 2,759
Current portion of
capital lease obligation -- 192
Current portion of
long-term debt 1,385 1,335
Deferred revenue 2,879 5,672
-------------------- --------------
Total current
liabilities 13,763 14,464
Capital lease obligation -- 201
Deferred revenue 784 --
Long-term debt 1,921 2,862
Other noncurrent liabilities 610 571
-------------------- --------------
Total liabilities 17,078 18,098
-------------------- --------------
Stockholders` equity:
Common stock 259 200
Additional paid-in capital 355,840 103,497
Deferred compensation on
stock options, net (1,061) (2,488)
Accumulated other
comprehensive loss -- (3)
Accumulated deficit (96,150) (78,138)
-------------------- --------------
Total stockholders`
equity 258,888 23,068
-------------------- --------------
Total liabilities and
stockholders` equity $ 275,966 $ 41,166
-------------------- -----------

[Meier M]

Servus zusammen

affx hat rechtstreit gewonnen könnte das für glgc sich nicht positiv auswirken, mtiggy?

mfg

[Meier M]

A More Controversial Road to Gene Mapping
Many biotech companies are using diseased tissue to try to solve the genetic
riddle behind deadly ailments -- but ethical and scientific doubts are making
it a tough sell


Retrieving malignant tumor tissue and diseased body
parts that surgeons have removed from sick patients
might seem a macabre way to benefit from the
ongoing biotech boom in DNA research. But Gene
Logic is doing just that. The Gaithersburg (Md.)
company sells subscriptions to the databases it has
built around its rapidly growing collection of tissue
samples.

Gene Logic isn`t alone. An increasing growing number of startup and established
outfits, including gene giant Incyte Genomics, now have tissue-collection
programs. They hope DNA replicated from these discards will provide a road
map to the diseases that brought the patients to the hospital in the first place.
Their work could mean powerful drugs against renal disease, skin cancer, and
other common ailments that kill millions of people each year.

SEARCHING GENE SETS. The sampling starts in operating rooms of teaching
hospitals around the world, where lab technicians place tumors or other excised
tissue into liquid nitrogen to freeze the chemically unstable genetic matter. The
samples are then shipped in plastic capsules to a central repository and matched
with the medical history of the donor. Researchers can then select a subset of
several thousand liver-tissue samples to search for a set of genes that contribute
to liver cancer, for example.

"Most of these diseases are associated with multiple genes," explains Kent
Bottles, director of the repository for the two-year-old startup Genomics
Collaborative of Cambridge, Mass. "Each one might be a target for a therapy or
a new diagnostic test."

Still, the stock market hasn`t warmed to Gene Logic. The company`s shares trade
in the $20 to $22 price range, down more than 80% from a March high of $152.
The decline reflects investor skepticism about a subscription model that has no
clear drug successes. Says John McCamant, editor of the Berkeley-based
Medical Technology Stock Letter: "Private companies I can understand doing
this. They can slowly show me how they are going to build the business model.
What is the business model for building tissue samples?"

CUTTING CORNERS? Collecting "body parts`` also might prove a tough ethical sell,
particularly as these companies look to foreign hospitals for sample collections.
Neither the Food & Drug Administration nor the National Institutes of Health
(NIH), which generally oversees medical experiments involving humans,
currently regulates tissue sampling. The temptation for companies intent on
cutting corners and costs to speed up sample collections at the expense of patient
consent could prove irresistible, particularly for foreign companies not subject to
U.S. laws or intense media scrutiny.

And some experts claim this method of tissue collection is an inexact science that
won`t bear fruit. Nonetheless, Gene Logic sees moneymaking cures at the end of
its ethical and scientific ordeal. "This whole area is rife with moral and ethical
issues but could be extremely valuable in terms of genetic information," says
Robert Burrows, Gene Logic`s vice-president for investor and corporate
relations.

The tissue-sampling approach differs from more traditional gene-mapping efforts
by Bethesda (Md.) genetic company Celera and an international nonprofit effort
coordinated by the NIH. These two groups are working to map the entire human
genome from samples of healthy cells in hopes of pinpointing which genes are
responsible for various areas of physical development. For example, the map
might show scientists which genes tell basic eye cells to redivide into corneal and
retinal cells. Scientists then might be able to learn how to formulate genetic
medicines specific to glaucoma. For its part, Incyte builds genetic databases
using both discarded tissue and the more traditional genome-mapping method.

"SENSITIVE SUBJECT." The size of the tissue-sampling industry is difficult to
determine due to the controversy surrounding it. Most companies refuse to reveal
the locations of teaching hospitals that have sample-collection programs in place.
Officials at Incyte and Gene Logic wouldn`t discuss their collection methods.
And the big Bay Area tissue-sample provider, privately held Clontech, won`t
even say whether its genetic material comes from U.S. or foreign sources. "It`s a
very sensitive subject," says Alicia Hunner, Clontech`s project manager.

Still, there`s some evidence that the industry is emerging from the closet. In
September, privately held Ardais Corp. of Lexington, Mass., announced that
Duke University School of Medicine in Durham, N.C., and Beth Israel
Deaconess Medical Center in Boston had agreed to provide the company with
leftover patient tissue in exchange for access to Ardais` tissue database. Beth
Israel owns about 5% of Ardais, which is financed by venture capitalists. (The
hospital pledged to plow back its profits from the deal into research.) And in July,
Bay Area startup DNA Sciences said it would sign up DNA donors on the
Internet. So far, 4,000 people have signed up, according to CEO Ray White.

By most accounts, the sampling has followed strict ethical guidelines thus far.
Patients here and abroad sign consent agreements after extensive briefings on
potential uses for their tissue. "We insist on exactly the same informed consent.
We train and audit them," says Bottles of Genomics Collaborative, which has
collections agreements with dozens of U.S medical centers and medical schools
in Vietnam, Tunisia, Poland, and India.

REVENUES ON THE RISE. High ethical standards and strong subscriber demand for
its database, however, have yet to drive Gene Logic to profitability. In the first
six months of 2000, the company lost $10 million, or 41 cents a share, on
operating expenses of $15.5 million and revenues of $11.5 million. Still, the many
big pharmaceutical companies -- including Pfizer, Procter & Gamble, and
American Home Products -- that have signed up for Gene Logic`s GeneExpress
genetic-database service helped push the company`s revenues in the first six
months of 2000 up 24%, to $11.5 million, compared to $9.3 million in the same
period last year.

But skeptics like editor McCamant say Gene Logic must come up with a new
business plan -- sooner rather than later -- to keep its share price from falling
further. Questions of ethics may be easier for the company to solve than figuring
out how to make money in the near term.

[mtiggy]

Meier M, hat es, hat es! + 13,5% an der Nasdaq. Das haben wir lange nicht gehabt. Hoffentlich
gehts weiter so.
mfg
mtiggy

[MatzeKlug]

Hoffen wir es mal dass die Rakete steigt. Denn Sequenom bringt mich noch zur Verzweiflung !!!

[Meier M]

Servus zusammen,

da ich schon am verzweifeln war ist mal wieder ein lichtblick in sicht.iadalbert ist eine
charttechnische 5 sterne bewertung ausgesprochen worden! AFFX wird uns hoffentlich
auf die reise etwas mirnehmen.

@matzeklug

hatte sqnm auch mal, anfangs für 24€ gekauft dann auf 19 runter (zitter) muß man durch
und am ende so 30 juni herum für 47 verkauft. GLGC hatte ich immer auf meiner liste
nur zu diesem zeitpunkt hätte ich sie nicht kaufen dürfen. nun mittlerweile hab ich auf
28$ verbilligen können. jetzt ist es mein baby aber wirklich ein baby da wo man in der
nacht teilweise nicht schlafen kann, hä,hä...

viel glück und einen erfolgreichen tag

m.m.

[Meier M]

Article for Gene Logic Inc (NASDAQ NM:GLGC)
4:45 PM



most recent headlines
next article:






The AEA Classic Conference to be Broadcast by Investor Broadcast Network Over the Internet
- Part 8


FRIDAY, NOVEMBER 03, 2000 4:45 PM
- BusinessWire

PHILADELPHIA, Nov 3, 2000 (BUSINESS WIRE) -- The AEA Classic will be broadcast by Investor Broadcast Network
beginning Monday, November 6 at 11:00 AM Eastern and continuing through Friday, November 10.

This press release contains only a partial list of presenting companies. A complete list of presenting companies can
be found at http://www.vcall.com/NASApp/VCall/EventPage?ID=52465." target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52465. Participating companies are subject to
change, so please check back often.

The following companies and speakers will be available for on-demand listening on Friday, November 10, 2000 at 8:00
AM Eastern:

-- Geoworks Corporation (NASDAQ: GWRX) executives at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52206" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52206

-- Digimarc Corporation (NASDAQ: DMRC) CFO E.K. Ranjit, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52204" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52204

-- Itron, Inc. (NASDAQ: ITRI) CEO LeRoy Nosbaum, and VP of IR,
Mima Scarpellui, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52208" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52208

-- Jacada Ltd. (NASDAQ: JCDA) President, Michael Potts, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52209" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52209

-- Gene Logic, Inc. (NASDAQ: GLGC) Director of Corporate
Communications, Robert Burrows, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52205" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52205

-- Applied Films Corporation (NASDAQ: AFCO) President and CEO,
Thomas Edman, and CFO, Lawrence Firestone, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52202" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52202

-- iManage, Inc. (NASDAQ: IMAN) President and CEO, Max Panjwani,
and CFO, Mark Culhane, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52207" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52207

-- Corillian Corporation (NASDAQ: CORI) CFO, Steve Sipowicz, and
EVP Corporate Development, Alex Hart, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52203" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52203

-- MSC.Software Corporation (NYSE: MNS) CEO and Chairman, Frank
Perna, at http://www.vcall.com/NASApp/VCall/EventPage?ID=52210" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52210

-- Prime Response, Inc. (NASDAQ: PRME) President and CEO, Peter
Boni, and CFO, Fred Phillips, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52211" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52211

This event is also available through Investor Broadcast Network`s Vcall.com and InvestorConference.com websites,
located at http://www.vcall.com, and http://www.InvestorConference.com, respectively. Listeners should go to one
website at least fifteen minutes before these events to download and install any necessary audio software. For those
unable to attend the live broadcast, a replay will be available for 90 days unless otherwise requested by a participating
company. There is no charge to access any event.

About Investor Broadcast Network

Investor Broadcast Network is the leading broadcaster of real-time investment information and analysis on the Internet.
With a complete portfolio of web-based broadcast communication services, the company gives investors access to the
inner circle of corporate executives and industry thought leaders, while providing public companies with an efficient
online investor relations strategy that meets their financial needs and reduces the high-risk of selective disclosure. For
more information on Investor Broadcast Network visit www.investorbroadcast.com

CONTACT: Investor Broadcast Network, Philadelphia
Kim Stever or Jaime Beal, 888/311-8225
4394-00 IBC
TICKERS: NASDAQ:GWRX NASDAQMRC NASDAQ:ITRI NASDAQ:AFCO
NASDAQ:JCDA NASDAQ:GLGC

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS
INTERNET
INSURANCE
CONFERENCE
CALLS
TRADESHOW

[Meier M]

Article for Gene Logic Inc (NASDAQ NM:GLGC)
4:45 PM



most recent headlines
next article:






The AEA Classic Conference to be Broadcast by Investor Broadcast Network Over the Internet
- Part 8


FRIDAY, NOVEMBER 03, 2000 4:45 PM
- BusinessWire

PHILADELPHIA, Nov 3, 2000 (BUSINESS WIRE) -- The AEA Classic will be broadcast by Investor Broadcast Network
beginning Monday, November 6 at 11:00 AM Eastern and continuing through Friday, November 10.

This press release contains only a partial list of presenting companies. A complete list of presenting companies can
be found at http://www.vcall.com/NASApp/VCall/EventPage?ID=52465." target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52465. Participating companies are subject to
change, so please check back often.

The following companies and speakers will be available for on-demand listening on Friday, November 10, 2000 at 8:00
AM Eastern:

-- Geoworks Corporation (NASDAQ: GWRX) executives at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52206" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52206

-- Digimarc Corporation (NASDAQ: DMRC) CFO E.K. Ranjit, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52204" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52204

-- Itron, Inc. (NASDAQ: ITRI) CEO LeRoy Nosbaum, and VP of IR,
Mima Scarpellui, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52208" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52208

-- Jacada Ltd. (NASDAQ: JCDA) President, Michael Potts, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52209" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52209

-- Gene Logic, Inc. (NASDAQ: GLGC) Director of Corporate
Communications, Robert Burrows, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52205" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52205

-- Applied Films Corporation (NASDAQ: AFCO) President and CEO,
Thomas Edman, and CFO, Lawrence Firestone, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52202" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52202

-- iManage, Inc. (NASDAQ: IMAN) President and CEO, Max Panjwani,
and CFO, Mark Culhane, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52207" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52207

-- Corillian Corporation (NASDAQ: CORI) CFO, Steve Sipowicz, and
EVP Corporate Development, Alex Hart, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52203" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52203

-- MSC.Software Corporation (NYSE: MNS) CEO and Chairman, Frank
Perna, at http://www.vcall.com/NASApp/VCall/EventPage?ID=52210" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52210

-- Prime Response, Inc. (NASDAQ: PRME) President and CEO, Peter
Boni, and CFO, Fred Phillips, at
http://www.vcall.com/NASApp/VCall/EventPage?ID=52211" target="_blank" rel="nofollow ugc noopener">http://www.vcall.com/NASApp/VCall/EventPage?ID=52211

This event is also available through Investor Broadcast Network`s Vcall.com and InvestorConference.com websites,
located at http://www.vcall.com, and http://www.InvestorConference.com, respectively. Listeners should go to one
website at least fifteen minutes before these events to download and install any necessary audio software. For those
unable to attend the live broadcast, a replay will be available for 90 days unless otherwise requested by a participating
company. There is no charge to access any event.

About Investor Broadcast Network

Investor Broadcast Network is the leading broadcaster of real-time investment information and analysis on the Internet.
With a complete portfolio of web-based broadcast communication services, the company gives investors access to the
inner circle of corporate executives and industry thought leaders, while providing public companies with an efficient
online investor relations strategy that meets their financial needs and reduces the high-risk of selective disclosure. For
more information on Investor Broadcast Network visit www.investorbroadcast.com

CONTACT: Investor Broadcast Network, Philadelphia
Kim Stever or Jaime Beal, 888/311-8225
4394-00 IBC
TICKERS: NASDAQ:GWRX NASDAQMRC NASDAQ:ITRI NASDAQ:AFCO
NASDAQ:JCDA NASDAQ:GLGC

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.

INDUSTRY KEYWORD: COMPUTERS/ELECTRONICS
INTERNET
INSURANCE
CONFERENCE
CALLS
TRADESHOW

[Meier M]

We were incorporated in September 1994 and have devoted substantially all of our resources to the
development of our genomics technologies, bioinformatics systems and database products for use in
pharmaceutical, diagnostic and agricultural product research and development.

Since 1997, we have developed custom gene expression databases designed for certain of our
customers` internal programs and needs and targeted to specific therapeutic areas of interest, including
heart failure, kidney disease, osteoporosis, psychiatric disorders and other major illnesses. Building on
this know-how, in March 1999, we began developing the GeneExpress Suite, our large-scale reference
database of gene expression information. The GeneExpress Suite contains information from a broad
range of normal and diseased human tissues, tissues from experimental animals, human and animal cell
lines and tissues that have been treated with many different drugs. We completed development of the
first commercial version of the GeneExpress Suite in November 1999. We currently market the
GeneExpress Suite through nonexclusive subscriptions to customers in the pharmaceutical,
biotechnology and diagnostic industries, and are developing versions of the database suite to market to
the academic and government life science research community and to physicians and patients. We
sold our first subscription to the GeneExpress Suite in December 1999.

Customers for our custom database and related software products can provide us with various
combinations of recurring technology and database access fees, research fees, certain additional
payments upon the attainment of research and product development milestones, royalty payments
based on sales of any products resulting from their use of our products, and nonrefundable upfront
payments. Subscribers to our GeneExpress Suite pay us varying database subscription fees depending
upon the level and type of information they obtain.

Technology and database access fees are recognized evenly over the term of each customer
agreement. We recognize revenues from research and development support when they are earned,
which is ordinarily when the work is performed or costs are incurred. Milestone payments and
royalties are recognized when they are earned in accordance with the applicable performance
requirements and

9.


contractual terms. Subscription fees to the GeneExpress Suite are recognized evenly over the term of
the subscription. Nonrefundable upfront payments received for the value of data purchased,
transferred technology or other contractual rights that are not contingent upon future performance
under the terms of the agreements are recognized as revenue when earned. Under collaboration
agreements in which we create research databases in exchange for fixed fees, revenues from such
collaborations are recognized on the percentage-of-completion method.

Our future profitability will depend in part on the successful establishment of agreements with
additional customers which include various combinations of genomic databases, bioinformatics
software and genomics technology and the successful commercialization of the GeneExpress Suite.
Payments for access to custom databases and the GeneExpress Suite are expected to be our primary
source of revenue for the foreseeable future. We have not received, and do not expect to receive,
significant royalty or other revenues from development and commercialization of products by our
customers using our databases and other technology for several years, if at all. Revenues from our
customers may be subject to significant fluctuation in both timing and amount, and, therefore, our
results of operations for any period may not be comparable to the results of operations for any other
period.

We have incurred operating losses in each year since our inception. At September 30, 2000, we had
accumulated losses of approximately $96.2 million. Our losses have resulted principally from costs
incurred in the development of our gene expression databases, a $35.2 million non-recurring charge
incurred in connection with our acquisition of Oncormed and selling, general and administrative costs
associated with our operations. These costs have exceeded our revenues which, to date, have been
generated principally from agreements for our custom database and related software products. We
expect to incur additional operating losses in future years.

RESULTS OF OPERATIONS

Three and Nine Months Ended September 30, 2000 and 1999

Revenues increased $1.0 million or 25% to $5.3 million for the three months ended September 30,
2000 from $4.2 million for the same period in 1999. Revenues increased $3.3 million or 25% to $16.8
million for the nine months ended September 30, 2000 from $13.5 million for the same period in 1999.
The increase in revenues resulted primarily from additional subscribers to the GeneExpress Suite of
products offset somewhat by a decline in custom database revenues due in part to the conclusion of a
collaboration with Aventis CropScience. Payments from each of American Home Products Corp.`s
Wyeth-Ayerst Laboratories, Genaissance Pharmaceuticals, Japan Tobacco and Procter & Gamble
accounted for 10% or more of revenue for the three months ended September 30, 2000. Payments
from each of Aventis CropScience, Japan Tobacco and Procter & Gamble accounted for 10% or
more of revenue for the three months ended September 30, 1999 and the nine months ended
September 30, 2000. Payments from each of Aventis CropScience, Japan Tobacco, Organon and
Procter & Gamble accounted for 10% or more of revenue for the nine months ended September 30,
1999.

Research and development expenses increased to $12.0 million and $31.0 million for the three and
nine months ended September 30, 2000, respectively, from $7.0 million and $21.5 million for the same
periods in 1999. The increase in research and development expenses for the three and nine month
periods ended September 30, 2000 was primarily attributable to increased tissue acquisition and
processing costs, Affymetrix GeneChips usage, and agreements with third parties to expand and
enhance the content and product offerings of the GeneExpress Suite. We expect research and
development expenses to increase as we expand the content of the GeneExpress Suite, further
develop the Flow-thru Chip and pursue our collaboration with Life Technologies, Inc.

Selling, general and administrative expenses increased to $4.7 million and $12.7 million for the three
and nine months ended September 30, 2000, respectively, from $2.3 million and $6.1 million for the
same periods in 1999. For the three and nine month periods approximately $1.9 million and $4.3 million,
respectively, of the increase was attributable to the establishment of sales and marketing efforts. The

10.


remainder of the increase is due to the expansion of general business operations. Selling, general and
administrative expenses are expected to increase as we expand our product offerings and sales and
marketing efforts.

Amortization of goodwill was $0.4 million and $1.1 million for the three and nine months ended
September 30, 2000, respectively, as a result of the acquisition of Oncormed in September 1998.

Net interest income increased to $3.8 million and $10.0 million for the three and nine months ended
September 30, 2000, respectively, from $0.1 million and $0.6 million for the same periods in 1999
primarily due to investment of the proceeds of our public offering of common stock in February 2000.

LIQUIDITY AND CAPITAL RESOURCES

From inception through September 30, 2000, we have financed our operations through the sale of
equity securities, payments from customers, and equipment and tenant improvement financing. In
February 2000, we completed a public offering of 4,680,000 shares of our common stock (including
exercise of the underwriters` over-allotment option), generating net proceeds of approximately $247.5
million. As of September 30, 2000, we have also obtained $0.5 million of capital lease financing and
$6.3 million under equipment and tenant improvement loans. As of September 30, 2000, we had
approximately $231.4 million in cash, cash equivalents and marketable securities, compared to $12.4
million as of December 31, 1999.

Net cash used in operating activities was $13.2 million for the nine months ended September 30, 2000
compared to $10.0 million for the same period in 1999. During the nine months ended September 30,
2000 and 1999, we primarily used cash to fund our operating losses.

The Company`s investing activities, other than sales, maturities and purchases of available-for-sale
securities, consisted of capital expenditures, an $8.1 million equity investment in NeuralStem and
software and database development costs. The increase in capital expenditures, which totaled $6.3
million and $2.8 million for the nine months ended September 30, 2000 and 1999, respectively, was
primarily due to increases in capacity needed to expand the content of the GeneExpress Suite of
products. During the fourth quarter of 2000 and the first quarter of 2001, we expect to invest
approximately $6.0 million in tenant improvements to meet our expanding facility requirements.

Software and database development costs were $5.2 million and $0.5 million for the nine months
ended September 30, 2000 and 1999, respectively. We incurred software development costs of $3.1
million and $0.5 million for the nine months ended September 30, 2000 and 1999, respectively, related
to ongoing efforts to enhance the software interface of the GeneExpress Suite. Also, during the three
months ended September 30, 2000 we incurred $2.2 million of database development costs related to
the update of our GeneExpress Suite data as a result of Affymetrix, Inc.`s release of their HU-95
Human Genome GeneChip set. This new set includes 60,000 human genes and ESTs as compared to
the HU-35 Human Genome GeneChip set which included 42,000 human genes and ESTs. Software
and database development costs are being amortized over their expected useful lives of three and two
years, respectively. Software development costs are expected to continue as a result of ongoing
efforts to further enhance the GeneExpress Suite while database development costs are not expected
to recur in the near future.

Our financing activities, other than the repayment of capital lease obligations and equipment loans,
consisted of the issuance of common stock primarily through our public offering in February 2000 and
the exercise of stock options.

We believe that existing cash and cash equivalents and anticipated payments from customers will be
sufficient to support our operations for the foreseeable future. These estimates are forward-looking
statements that involve risks and uncertainties. Our actual future capital requirements and the
adequacy of

11.


our available funds will depend on many factors, including those discussed in our Annual Report on
Form 10-K for the year ended December 31, 1999 and the following:

- progress of our discovery programs;

- the number and breadth of these programs;

- our ability to establish and maintain additional arrangements with customers, including additional
subscriptions to the GeneExpress Suite;

- the commercial success of the in-process technologies we acquired in our acquisition of Oncormed;

- the progress of the development and commercialization efforts of our customers;

- the level of our activities relating to our independent discovery programs and to the development and
commercialization rights we retain in our arrangements with customers;

- competing technological and market developments;

- the costs associated with obtaining access to tissue samples and related information; and

- the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other
intellectual property rights.

We could require additional financing in the future, which we may seek to raise through public or
private equity or debt offerings. To the extent that we raise additional capital by issuing equity or
convertible debt securities, ownership dilution to stockholders will result. If adequate financing is not
available when needed, we may be required to:

- curtail significantly one or more of our research and development programs;

- obtain funds through arrangements with customers that may require us to relinquish rights to certain
of our technologies, discoveries or potential products; or

- grant licenses on terms that are not favorable to us.

12.

[Meier M]

Gene Logic on Track to Have 3 More Database
Subscribers in `00
By Karen Fessler

New York, Nov. 27 (Bloomberg) -- Gene Logic Inc. said it`s on track to license
its gene expression databases to at least three more companies by the end of
the year and generate about $25 million in revenue this year, a top executive
said.

Gene Logic, with $19.2 million in sales last year, creates databases of genetic
information that provide researchers with details on how genes interact, how
they`re expressed and their effects on cells and tissues so they can develop
new drugs.

The money-losing company has so far this year licensed its GeneExpress
suite of databases to seven subscribers, including Pfizer Inc. and American
Home Products Corp., and is targeting a mix of pharmaceutical and
biotechnology companies. The target market for Gene Logic`s databases
could eventually reach about $1.15 billion in annual sales, said Chief
Executive Mark Gessler.

Gaithersburg, Maryland-based Gene Logic charges pharmaceutical
companies about $4 million to $6 million and biotech companies about $2
million for subscriptions to the databases.

Gessler spoke to investors at the BankBoston Robertson Stephens medical
conference today in New York.

[tjatja]

Bedeuten DatenAbkommen Biotech Reales Geld?

Neue Tage und Wochen haben bessere Abkommen für Entwicklung-Stadium bioinformaticsfirmen geholt. Genlogik hat dreijährige Subskription Abkommen, wert $1,5 Million bis $5 Million ein Jahr, mit einer atemlosen Kinetik verkündet. Incytes sackten erhaltene Prahlenrechte auch und Celera gerade ein, was wie ein Konkurrent -- Genset Frankreichs ausgesehen hatte. Die geöffnete Frage ist, ob diese Firmen (und Notwendigkeit) entwickeln ihre eigenen Drogen, um die grosse Zeit zu schlagen einmachen.

Durch Tom Jacobs (Tmf Tom9) Januar 10, 2001

Die Abkommen Biotech, die an den letzten Tagen verkündet werden, markieren die heißeste Debatte in der biotechwelt: Wenn und wie bioinformaticsfirmen -- die Gleichen von Genlogik (Nasdaq: Glgc), Incyte Genomics (Nasdaq: INCY) und Celera Genomics (NYSE: CRA) -- kann langfristigen Geschäft Erfolg unterstützen. Können sie ihre Informationen alleine verkaufen, beschaffen Sie zukünftige Meilensteinzahlungen und -abgaben auf den Drogen oder Diagnose, die aus ihren Daten produziert werden, oder müssen sie Drogeverwertungsgesellschaften selbst stehen?

Sie können auf dieser Debatte auch sich wiegen sich, indem Sie eins von vielen smokin` Gewinde auf dem Brett Diskussion Celera über die Subskription, die Abgaben und/oder das Drogeentwicklung Dilemma für die Firmen verbinden, die mit den genomic und proteomic Informationen reich sind.

Schnelle Feder der Genlogik die Abkommen sind schnell und furiously gekommen. Genlogik unterzeichnete gestern pharmazeutische Produkte Sumitomo zu den Subskription Abkommen für zwei Teile seiner kompletten GeneExpress-Suitedatenbank und folgte einer Überflutung von Vereinbarungen im letzten Monat mit IDEC-pharmazeutischen Produkten (Nasdaq: Idph), Procter U. Glücksspiel (Nyse: Seite), Boehringer Ingelheim, Biogen (Nasdaq: BGEN) und Organon. Die meisten diesen sind für Zugriff zum kompletten GeneExpress-Suite der Firma, den die Firma sind dreijährige Abkommen mit $1,5 Million bis $5 Million ein Jahr in den Gebühren sagt. Der Pakt Biogen ist für kundenspezifische Dienstleistungen.

Herzog Incyte und Celera es aus Incytes geraden verkündeten Vereinbarungen Technologien mit des Messens und der Prüfung riesige Agilent (NYSE: A) und Materialelektrizitätskraftwerk Corning (Nasdaq: GLW), das Daten Incytes und Genpatente genehmigt, um Biochips, Einheiten aufzubauen und zu verbessern, um DNA. Yesterday zu prüfen und zu analysieren, Celera unterzeichnete Genset Frankreichs (Nasdaq: GENXY) als Kunde, damit seine Datenbanken, Software und supercomputing Energie den Drogeentdeckung- und -entwicklungsprozeß, während heute die maximale Gesellschaft Planck für Zuführung der Wissenschaft in Deutschland, das Karolinska Institutet in Schweden und die Universität von Tokyo in Japan, stand Kunden Celera erhöht. Celeras, das in den letzten Monaten vielen akademischen Kunden verkündet werden, und es laden sie gewöhnlich weniger auf, als es Handelsgesellschaften tut.

Ein interessantes sidelight ist Trompete Pressekommuniqué dieses Incytes " die führende genomicsinformationen Firma.", Nehmen Sie das, Celera, dessen " Mission ist, die endgültige Quelle der genomic und in Verbindung stehenden medizinischen Informationen zu werden.", Ich liebe gerade einen guten Kampf, nicht Sie?

Die Bezeichnungen nicht nicht, die überraschend, die Firmen freigegeben werden, geben nicht die genauen finanziellen Bezeichnungen frei, obwohl Genlogik über die Strecke der Subskription Gebühren ($1,5 bis $3 Million) und der Einkommen Ziele erfrischend direkt gewesen ist ($100 Million ein Jahr einige Jahre heraus). Weil Genlogik- und -Celerapressekommuniqué leise sind, können wir annehmen, daß die Abkommen nicht -- wie Incytes -- Bestimmungen für Meilensteinzahlungen umfassen und Abgabezahlungen für die Produkte, die von den Daten entwickelt werden, stellt zur Verfügung. Erkundigend möchten Investoren wissen, ob Kunden bereit sind, entweder erhebliche Subskription Gebühren oder aussagefähige Meilensteinzahlungen und -abgaben zu bewilligen, aber nicht beide.

Genlogik und -Incyte sind zwei reine bioinformationfirmen deren Geschäfte in der Nichtdrogeentwicklung Richtung -- hübsches offenbar spitzes sind und ihre Unternehmenspläne gut durchführen. Sie können in ihrer aktuellen Form, anders als den Durchlauf der Drogeentdeckung-Plattformfirmen überleben -- Firmen deren alleiniger Unternehmensplan, irgendeine ordentliche Weise für grosse Drogehersteller wie Richtlinie Hersteller-Mappe Holdings Pfizer zur Verfügung zu stellen ist (NYSE: PFE) oder Schering-Plough (NYSE: SGP) oder amerikanische Hauptprodukte (NYSE: AHP) zum Entwickeln der Drogen -- daß ich vereinige oder ausfalle argumentiert habe.

Celera und bioinformatics betrachtend, gibt es die wie Compugens (Nasdaq: CGEN-) Vorsitzender und CFO, Martin Gerstel, der in einem Interview mit dem Dummkopf opined, daß Zukunft der bioinformatics` nicht rechnende Energie, aber fachkundige molekulare Biologiesoftware ist. Kontrastieren Sie das mit Präsidenten und wissenschaftlichem Kommentar OffizierCraig Hauptsächlichventer Celeras, daß rechnende Fähigkeit Beschränkungen seine Industrie rückseitig! anhalten).

Das könnte mehr Druck bedeuten, damit Celera mehr als beachtliche Rückkehr erwirbt, indem es an Drogen sich wendete, die das Potential für drastische Rückkehr anbieten, wie von Amgen demonstriert (Nasdaq: AMGN) und seine Schutzkappe des Marktes $65 Milliarde basiert auf Verkäufen von zwei Knüllern. David Langford hat argumentiert, daß Notwendigkeit Celera nur in den Meilenstein und die Abgabesoßeserie zum Nutzen -- als Pläne Incyte zu -- von anderen Entwicklung der Drogen von seinen Daten einsteigen.

Konnte Celera seine eigenen Drogen entwickeln? Aber konnte Celera vollständiges gehen Schwein und Drogen entwickeln selbst? Mit über $1 Milliarde im Bargeld und in den kurzfristigen Äquivalenten (pro 10-q für den Viertelendesept. 30), ist Celera vermutlich das einzige des bioinformaticsbündels, das Drogeentwicklung sich aufnehmen könnte, ohne zu viel Billigkeit oder Rechte zu verkaufen zu den grossen Drogeherstellern gegen die Drogeentwicklung Finanzierung. Erinnern Sie daran sich, daß das Drogebilden bodenlose Taschen benötigt: Als Faustregel nimmt es 10 Jahre und $500 Million, um sich zu entwickeln und zu holen, um eine erfolgreiche Droge zu vermarkten.

Amgens erster CEO, George Rathmann, erklärte den Zeiten neuen Yorks vor kurzem, daß er denkt, daß Celera ` Venter, zu intelligent ist nicht innen zu verbinden. (Sie können unseren Artikel auf Rathmann und anderem neuem dummem biotechinhalt auf unserem InDepth finden: Biotechnologieseite.) Investoren Celera -- wie ich -- werden nah überwachen.

Sie können Ihre Biotechnologie, die Fähigkeiten, indem Sie investieren die Motley Anleitung des Dummkopfs zu investierendem Biotech oder den Motley Industrie,fokus 2001 auch kaufen schärfen des Dummkopfs, der die Biosubstanz- und genomicshilfsmittelindustrien analysiert.

[Meier M]

Gene Logic Launches New GeneExpress Product--Cardiovascular DataSuite

Further Step Toward Comprehensive Coverage of Human Biology

GAITHERSBURG, Md.--(BW HealthWire)--May 15, 2001--Gene Logic Inc. (Nasdaq:GLGC - news) announced today that it has
launched a new GeneExpress® Suite product, the GeneExpress® Cardiovascular DataSuite, for use in pharmaceutical and
biotechnology companies` cardiovascular drug discovery and development programs.

Gene Logic`s cardiovascular program and, specifically, the Cardiovascular DataSuite, is representative of the Company`s ongoing
initiative to introduce information products that directly address the critical research and development needs in drug development.

The Cardiovascular DataSuite, a subset of the GeneExpress® Suite, is comprised of a diverse set of normal and diseased human
cardiac and vascular tissues from a broad cross-section of individuals, races, medication regimens, lifestyles, disease stages and other
demographic and/or clinical parameters.

Representative samples include key cardiac and vascular disease states, including atherosclerosis, coronary artery disease,
hypertension, congestive heart failure, stroke, peripheral vascular disease, arteriopathies, venous thrombosis and arrhythmia.

The Cardiovascular DataSuite will also contain relevant in vitro and in vivo disease animal model systems related to cardiovascular
indications, which will provide a critical basis for comparison between non-human and human disease models.

Based upon the quality of samples and the corresponding data contained in the Cardiovascular DataSuite, researchers will be able to
use this product to identify potential new drug targets, as well as identify surrogate markers for diagnosis, progression and prognosis
of cardiovascular diseases.

The DataSuite also allows for identification of overlapping expression patterns which may indicate common pathways across multiple
cardiovascular diseases which can enable researchers to discover alternative targets for existing drugs, as well as prioritize multiple
potential drug targets.

Furthermore, the Cardiovascular DataSuite will enable researchers to potentially predict various cardiotoxic indications, including
Long QT Syndrome (LQTS), Torsades de Pointes (TdP) and drug induced valvular disease.

As with all GeneExpress® Suite products, the Cardiovascular DataSuite will include access to Gene Logic`s comprehensive
GeneExpress® 2000 data management and analysis software platform, which includes robust mining, visualization and analysis tools,
as well as links to all disease pathways unique to each cardiovascular disease indication represented.

Subscribers to the Cardiovascular DataSuite will also receive updates to both the cardiovascular content and the bioinformatics tools
on a regular schedule.

``We are extremely pleased to launch the Cardiovascular DataSuite, the latest in a series of disease focused solutions for our customers,`` commented David S. Murray,
Senior Vice President, Marketing and Sales for Gene Logic. ``The Cardiovascular DataSuite is an extension of our mission to provide value-added gene expression
information solutions that directly address the critical research and development needs of the pharmaceutical and biotechnology communities. We are confident this
DataSuite will be instrumental in accelerating the discovery and development of cardiovascular therapeutic targets and diagnostic indicators.``

Gene Logic Overview

Gene Logic Inc. is a leading supplier of integrated biological information and bioinformatics related to gene activity in human disease and toxicity to enable global
pharmaceutical, biotechnology and life science companies to reduce the time, risk and cost involved in developing drugs against human disease.

Through the systematic and industrialized application of genomics, the Company provides a growing portfolio of biological information products, including the Company`s
flagship product, the GeneExpress® Suite of databases, and custom, proprietary gene expression databases focused on single disease indications.

A growing number of global pharmaceutical and biotechnology companies utilize Gene Logic`s various biological information solutions throughout their drug discovery
and development programs. For more information about Gene Logic, visit the company`s Web site at www.genelogic.com or telephone toll-free on 800/GENELOGIC.

All statements in this press release that are not historical are considered forward-looking statements within the meaning of Section 21E of the Securities Exchange Act
of 1934, as amended, including statements regarding Gene Logic`s ``expectations,`` ``beliefs,`` ``goals,`` ``hopes,`` ``strategies,`` or the like.

Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Gene Logic from those projected, including, but not limited to,
risks and uncertainties relating to technological approaches, product development, production, market acceptance, cost and pricing of Gene Logic products, utility of
genomic information in drug discovery and development, dependence on collaborative partners, sole source suppliers, competition, ability to sign new subscribers,
customer renewals and terminations, intellectual property of Gene Logic and others, and patent protection and litigation.

These and other risk factors are discussed in Gene Logic`s Annual Report on Form 10-K for the year ended December 31, 2000 and Gene Logic`s other SEC reports,
including its Quarterly Reports on Form 10-Q.

Gene Logic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect
any change in Gene Logic`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.